Healthcare

Did Abivax Just Quash Acquisition Rumors by Eli Lilly — and What It Means for Its IBD Breakthrough Asset?

January 26, 2026 — Paris & Global — Abivax SA, the French clinical‑stage biotechnology company, this week publicly dismissed speculation…

ByByAnuja Singh Jan 26, 2026

Could Sun Pharma’s Bold Bid for Organon Redefine Its U.S. Strategy and Global Footprint?

January 25, 2026 — Mumbai & New York — Sun Pharmaceutical Industries Ltd. (Sun Pharma), India’s largest pharmaceutical company, has…

ByByAnuja Singh Jan 26, 2026

Are AI Healthcare Tools Raising Ethical and Access Concerns?

January 26, 2026 | AI in Healthcare | Ethics, Equity & Policy Recent commentary in leading medical and…

ByByAnuja Singh Jan 26, 2026

Can GSK’s New Leadership Translate into Multi-Franchise Growth in 2026?

Late January 2026 | Full-Year 2025 Earnings Preview | Vaccines, Immunology & Specialty Care GlaxoSmithKline (GSK) is set…

ByByAnuja Singh Jan 26, 2026
Image Not Found

Blackstone’s $400M Bet on Teva–Sanofi Gut Drug Signals a Major Shift in the IBD Landscape

Blackstone has invested $400 million into Teva and Sanofi’s experimental ulcerative colitis (UC) and Crohn’s disease therapy, marking one of…

ByByAnuja Singh Mar 5, 2026

Has China Now Overtaken the US at the Heart of Biotech Innovation?

Recent data from JPM2026 shows that China has surpassed the United States in key biotech activity measures—topping the…

ByByAnuja Singh Mar 4, 2026
Scroll to Top